| |
Risk Assessments for Hazardous Chemicals and
Pharmaceuticals
RBDI performs risk assessments for human
health and ecological species for
regulatory compliance, primarily as
plug-in to algorithms developed by the
USEPA or by various state regulatory
agencies.
RBDI also uses
quantitative
risk assessments for decision-making
in a wide range of non-regulatory
situations and as a litigation support
tool.
In such instances, RBDI’s
quantitative approach allows our clients
to make better-informed financial
decisions on liabilities or between
different alternatives.
Since 2003, the Food and Drug Administration (FDA)
has also recommended the use of risk-based
approaches to evaluate Good manufacturing Practices
(GMP) and the assessment of pharmaceuticals in waste
streams (http://www.gmp-compliance.org/eca_news_309.html).
RBDI has assisted pharmaceutical
manufacturers in the US ad overseas in compliance
with these FDA protocols.
 |
RBDI scientists have evaluated multiple pharmaceutical facilities in several
countries and developed a single
risk-based approach to guide
the company in meeting or exceeding
standards in every country.
|
|
|
RBDI used a
risk-based approach to assist its client in
the design and QA/QC protocols for chemical
manufacturing facilities
in a developing
country.
|
|
|
|
